Drug intelligence / Profile preview

Qingxue Granule

Development stage: Preclinical
Lead developer: Xiyuan Hospital
Administration: Oral

Overview

Qingxue Granule is a Traditional Chinese Medicine (TCM) in granule form, developed by Xiyuan Hospital, China Academy of Chinese Medical Science. It is currently under investigation for its efficacy and safety in improving immune-related cutaneous adverse events in patients with advanced malignant tumors. As a TCM formulation, its therapeutic effects are likely mediated through a multi-component, multi-target approach, potentially involving immunomodulatory and anti-inflammatory pathways, although its precise herbal composition and detailed mechanism of action are not publicly available.

Beyond the preview

Go deeper on Qingxue Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingxue Granule.

Explore the full profile